Mycoprotein Consumption and Glucose Absorption

Healthy Clinical Trial

— MEGA  

Official title:

To Determine the Effects of Mycoprotein Consumption on Glucose Absorption in Healthy Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04084639
• Other study ID #: 190206/B/06
• Status: Completed
• Phase: N/A
• Start date: August 28, 2019
• Est. completion date: October 16, 2019

Study information

• Verified date: November 2019
• Source: University of Exeter
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Previous research has demonstrated that the food found in Quorn 'Mycoprotein' can lower the blood glucose response to a meal, which may be an important finding for the management of type 2 diabetes. However, it has never been investigated how this lower response occurs, and whether there is dose-dependent response with mycoprotein. The present study will include 12 healthy young adults, who will visit the laboratory for 3 test days, with each day lasting 9 hours. On each visit, separated by a washout period of at least 2 weeks, participants will ingest either a control drink with no mycoprotein, a drink containing 20g mycoprotein or a drink containing 40g mycoprotein. By intravenously infusing labelled glucose during each visit in combination with repeated blood sampling, investigators will determine if the lower blood glucose after mycoprotein ingestion is due to reduced glucose absorption from the gut or increased uptake into body tissues.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: October 16, 2019
• Est. primary completion date: October 16, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Male and female

• 18-35 years of age

• Consumption of sufficient amounts of carbohydrate in the diet

• Body mass index between 18.5 and 30

Exclusion Criteria:

• Any diagnosed metabolic impairment (e.g. type 1 or 2 Diabetes), or other form of abnormal glucose metabolism (as this will affect outcome of the study).

• Any diagnosed cardiovascular disease

• Insufficient consumption of carbohydrate in the diet

• A personal or family history of epilepsy, seizures or schizophrenia

• Known pre-existing liver disease/condition

• Allergy or intolerance to milk

Related Conditions & MeSH terms

• Healthy

Intervention

Dietary Supplement:
• Mycoprotein Ingestion
Ingestion of various doses of mycoprotein compared to placebo control

Locations

Country	Name	City	State
United Kingdom	University of Exeter	Exeter

Sponsors (2)

Lead Sponsor	Collaborator
University of Exeter	Quorn Foods

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glucose absorption	How glucose is absorbed following the ingestion of a mycoprotein drink compared to a placebo control measured using the infusion of stable isotopes	6 hours following ingestion of drink
Secondary	Incretin Hormones	Measurement of glucagon-like peptide-1(GLP-1) and gastric inhibitory polypeptide (GIP) in response to mycoprotein ingestion compared to placebo control	6 hours following ingestion of drink
Secondary	Insulinaemic Response	Measurement of insulin response following ingestion of drinks	6 hours following ingestion of drink
Secondary	Production of Short-Chain Fatty Acids	Measurement of plasma acetate production in response to mycoprotein ingestion	6 hours following ingestion of drink
Secondary	Glucose Kinetics	Calculations using plasma deuterated glucose enrichment to determine rate of appearance of endogenous glucose, rate of disappearance of glucose and rate of appearance of exogenous glucose	6 hours following ingestion of drink